DexCom (DXCM) Declines on Potential Competition for Stelo [Yahoo! Finance]
DexCom, Inc. (DXCM)
Last dexcom, inc. earnings: 4/28 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
dexcom.com/investors
Company Research
Source: Yahoo! Finance
The FDA approval for Stelo in March 2024 looked promising as it was the first and only continuous glucose monitoring (CGM) device to receive approval for its over-the-counter (OTC) availability as a glucose biosensor. Stelo represents a significant opportunity as it can be used to get glucose insights directly on a smartphone without a prescription. The company planned the launch of Stelo this summer for use by people aged 18 years and above who are not on insulin therapy. However, the FDA approval of Abbot 's ABT Lingo as an OTC glucose monitor should fuel potential competition for DexCom in this new category of over-the-counter CGM. Although Abbot is yet to announce its launch plan for Lingo in the United States, the product is already available in the United Kingdom since last year as a sensor for people who don't have diabetes to track glucose spikes. Price Performance Shares of DexCom have lost 7.2% year to date against the industry's 5% growth. The S&P 500 Index has risen
Show less
Read more
Impact Snapshot
Event Time:
DXCM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DXCM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DXCM alerts
High impacting DexCom, Inc. news events
Weekly update
A roundup of the hottest topics
DXCM
News
- Contact Levi & Korsinsky by October 21, 2024 Deadline to Join Class Action Against DexCom, Inc. (DXCM)Accesswire
- DXCM FRAUD UPDATE: DexCom, Inc. Investors are Encouraged to Contact BFA Law before the Expiration of the October 21 Legal Deadline in Securities Fraud CaseAccesswire
- ROSEN, A LONGSTANDING LAW FIRM, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCMGlobeNewswire
- Levi & Korsinsky Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 21, 2024 - DXCMAccesswire
- Shareholders of DexCom, Inc. Should Contact Levi & Korsinsky Before October 21, 2024 to Discuss Your Rights - DXCMAccesswire
DXCM
Earnings
- 7/25/24 - Beat
DXCM
Sec Filings
- 9/17/24 - Form 4
- 9/16/24 - Form 144
- 9/11/24 - Form 4
- DXCM's page on the SEC website